Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults

Opus Genetics, Inc. has received FDA approval for its supplemental New Drug Application for phentolamine ophthalmic solution 0.75% to treat presbyopia in adults. This approval will result in a milestone payment to Opus Genetics as part of its global licensing agreement with Viatris Inc., which grants Viatris exclusive rights to commercialize the product in the U.S.